Calluna Pharma

Fibrosis lungs
#3D imaging #Artificial intelligence (AI) #Calluna Pharma #Idiopathic pulmonary fibrosis #Imaging #Phase II trial #Qureight

AI 3D imaging platform supports Calluna’s IPF trial

Calluna Pharma will use Qureight’s AI-powered imaging and clinical data curation platform to support its Phase II AURORA study.   Qureight will analyse imaging data from adult patients, evaluating anatomical lung changes in individuals treated with CAL101, Calluna’s lead asset for the treatment of idiopathic pulmonary fibrosis (IPF). Read More

#News

#Arxx Therapeutic #Calluna Pharma #Funding #Immune system #Monoclonal antibodies #Oxitope Pharm #Therapeutic Antibodies

Calluna Pharma announces €75 million Series A financing 

Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, has announced their merger to form Calluna Pharma.   Calluna has raised €75 million in a series A financing and is backed by Oxitope… Read More

#Business & Investment #News